Erivedge® (vismodegib) is a capsule taken once daily to treat adults with a type of skin cancer, called basal cell carcinoma that has spread to other parts of the body or cannot be treated effectively with surgery or radiation. Erivedge works by blocking abnormal functioning of the Hedgehog cell signalling pathway. Abnormal activation of this pathway is responsible for tumour development in most basal cell carcinomas. Erivedge is approved in the United States, the European Union, Switzerland and many other countries across the world.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.